Nukkleus (NUKKW) has had the highest return since January 1, 2025 by a US stock with a market cap of $2,018+, returning 564.1%.
| ASSET | % RETURN |
|---|---|
Nukkleus (NUKKW) | 564.12% |
Wang & Lee Group, Inc Ordinary Shares (WLGS) | 333.33% |
Cyclo Therapeutics (CYTHW) | 328.57% |
Fubotv (FUBO) | 252.31% |
Dominari (DOMH) | 215.31% |
WM Technology (MAPSW) | 201.72% |
Oncology Institute (TOI) | 188.33% |
Noodles (NDLS) | 171.52% |
Invivyd (IVVD) | 165.96% |
Reborn Coffee (REBN) | 161.4% |
Chromocell Therapeutics (CHRO) | 156.72% |
N2OFF (NITO) | 154.66% |
Rapid Micro Biosystems (RPID) | 151.65% |
Nuvve (NVVEW) | 136.22% |
Society Pass (SOPA) | 135.29% |
Nvni Group Limited Ordinary Shares (NVNI) | 134.29% |
INNOVATE (VATE) | 131.7% |
GH Research (GHRS) | 123.49% |
Oklo (OKLO) | 120.87% |
Unity Biotechnology (UBX) | 120.79% |
Monopar Therapeutics (MNPR) | 118.18% |
Coeptis Therapeutics (COEP) | 117.27% |
Neuronetics (STIM) | 109.09% |
Compass Therapeutics (CMPX) | 108% |
Akero Therapeutics (AKRO) | 100.89% |
